InnoCare Pharma

InnoCare Pharma (HKEX:09969；SSE：688428) is a commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Guangzhou, Shanghai, Hong Kong, New Jersey and Boston. 

InnoCare has a fully-integrated biopharmaceutical platform with strong in-house innovation capabilities, holding multiple foreign and domestic patents with a rich product pipeline targeting liquid tumors, solid tumors, and autoimmune diseases. On March 23, 2020, InnoCare was successfully listed on Hong Kong Stock Exchange, and the Company got listed on STAR Board of Shanghai Stoch Exchange on September 21, 2022.

Founded in 2015, InnoCare was co-founded by Dr. Jasmine Cui, who has extensive experience in new drug development and business management and the world-renowned structural biologist Dr. Yigong Shi. Based on the core value of "Science drives innovation for the needs of patients", InnoCare has developed a robust pipeline which consist of 13 valuable assets, including two commercialized products, more than 30 ongoing global trials in various clinical stages. By now, InnoCare has built up a fully-integrated platform with consistently strong execution and a clear growth strategy in terms of research and development, clinical development, manufacturing and commercialization.